Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Statement re Possible Merger

28 Aug 2019 14:59

RNS Number : 4528K
Maven Income & Growth VCT 4 PLC
28 August 2019
Β 

Maven Income and Growth VCT 4 PLC

Maven Income and Growth VCT 6 PLC

Β 

Possible merger of Maven Income and Growth VCT 4 PLC ("Maven VCT 4") and Maven Income and Growth VCT 6 PLC ("Maven VCT 6") (together the "Companies")

The boards of directors of the Companies announce that they have entered into discussions regarding a possible merger of the Companies (the "Merger"). These discussions may or may not lead to an agreement to merge the Companies. If the Merger is to proceed, the current intention is that it will be undertaken by way of a scheme of reconstruction under s.110 of the Insolvency Act 1986 by transferring the assets and liabilities of Maven VCT 6 to Maven VCT 4 in consideration for the issue of new ordinary shares in Maven VCT 4 to the Maven VCT 6 shareholders on a relative net asset value basis. Although it is proposed that the merger would be undertaken under provisions set out in the Insolvency Act 1986, it would nevertheless be a solvent liquidation. A merger solely on this basis would not be governed by The City Code on Takeovers and Mergers.

If the Merger is to proceed, it will require formal approval from the shareholders of both Companies and would also be subject to any required regulatory approvals. If the Merger is approved, it is expected to achieve costs savings through the establishment of a larger combined entity. It is anticipated that the Prospectus and Circulars required under the Listing Rules and companies' legislation would be despatched to shareholders in early November 2019, with shareholder general meetings taking place in early December 2019 and completion in mid-December 2019.

A further announcement will be made in due course.

The information contained within this announcement is deemed by the Companies to constitute inside information as stipulated under the Market Abuse Regulations (EU number. 596/2014). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

For additional information, please contact:

Maven Capital Partners UK LLP

Secretary to the Companies

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

Β 

28 August 2019

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
STRUWVORKNAWUAR
Date   Source Headline
19th Nov 201811:40 amRNSDirector/PDMR Shareholding
15th Nov 20183:36 pmRNSDirectorate Change
15th Nov 20183:01 pmRNSMerger Update: Approval of Scheme
8th Nov 20184:27 pmRNSNet Asset Value(s)
1st Nov 201812:31 pmRNSResult of General Meeting
8th Oct 20187:00 amRNSStatement re Proposed Merger
14th Sep 20183:37 pmRNSHalf-year Report
13th Sep 20186:16 pmRNSPossible Merger
31st Aug 20184:04 pmRNSNet Asset Value(s)
22nd Jun 20184:30 pmRNSIssue of Equity
15th Jun 20184:47 pmRNSStatement re DIS
18th May 20184:47 pmRNSNet Asset Value(s)
17th May 20184:30 pmRNSDividend Declaration
15th May 20181:49 pmRNSResult of AGM
24th Apr 20184:52 pmRNSIssue of Equity
13th Apr 201812:48 pmRNSIssue of Equity
13th Apr 201811:59 amRNSPublication of Suppl.Prospcts
6th Apr 20184:41 pmRNSStatement re Dividend Investment Scheme
6th Apr 20184:34 pmRNSAnnual Financial Report
6th Apr 20189:23 amRNSDirector/PDMR Shareholding
6th Apr 20189:22 amRNSDirector/PDMR Shareholding
5th Apr 20186:23 pmRNSIssue of Equity
27th Mar 20185:44 pmRNSPublication of Suppl.Prospcts
8th Mar 20183:30 pmRNSDividend Declaration
6th Mar 20185:24 pmRNSTransaction in Own Shares
2nd Mar 201812:34 pmRNSStatement re Offer for Subscription
26th Feb 20184:25 pmRNSNet Asset Value(s)
6th Feb 20185:19 pmRNSDirector/PDMR Shareholding
6th Feb 20185:18 pmRNSDirector/PDMR Shareholding
6th Feb 20185:06 pmRNSIssue of Equity
24th Jan 20184:46 pmRNSPublication of Suppl.Prospcts
24th Jan 20184:41 pmRNSPublication of Suppl.Prospcts
30th Nov 20174:27 pmRNSIssue of Equity
22nd Nov 20173:01 pmRNSTransaction in Own Shares
21st Nov 20173:45 pmRNSIssue of Equity
17th Nov 20175:09 pmRNSStatement re NAV and Dividend Investment Scheme
9th Nov 20173:58 pmRNSNet Asset Value(s)
8th Nov 201710:10 amRNSResult of General Meeting
25th Oct 20173:00 pmRNSDividend Declaration
18th Oct 201710:43 amRNSReplacement Statement re Listing Application
17th Oct 20172:49 pmRNSStatement re Listing Application
22nd Sep 20176:25 pmRNSStatement re Offer for Subscription
22nd Sep 20176:25 pmRNSStatement re Offer for Subscription
15th Sep 20174:48 pmRNSIssue of Equity
15th Sep 201710:08 amRNSStatement re NAV and Dividend Investment Scheme
8th Sep 20177:00 amRNSHalf-year Report
6th Sep 201711:37 amRNSForm 8.3 - Byotrol Plc
29th Aug 20174:11 pmRNSNet Asset Value(s)
10th Aug 20174:38 pmRNSDividend Declaration
25th Jul 201712:55 pmRNSForm 8.3 - Work Group PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.